Showing results (1021-1030 of 2,283) with videos related to
Sort By:
Pageof 229
HIV Medicine|January 28, 2014
Switch from tenofovir to raltegravir increases low bone mineral density and decreases markers of bone turnover over 48 weeksM Bloch, W W Y Tong, J Hoy, et al.HIV Medicine|October 24, 2012
Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trialC Orkin, E DeJesus, H Khanlou, et al.HIV Medicine|January 15, 2014
Community HIV-1 drug resistance is associated with transmitted drug resistanceM W Tilghman, J Pérez-Santiago, G Osorio, et al.HIV Medicine|June 4, 2014
Younger age, recent HIV diagnosis, no welfare support and no annual sexually transmissible infection screening are associated with nonuse of antiretroviral therapy among HIV-positive gay men in AustraliaL Mao, J B de Wit, S C Kippax, et al.HIV Medicine|June 5, 2014
Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C virus-coinfected patientsD L Braun, A Rauch, N Durisch, et al.HIV Medicine|June 13, 2014
The cascade of care in the Eastern European country of GeorgiaN Chkhartishvili, L Sharavdze, O Chokoshvili, et al.HIV Medicine|January 22, 2015
Treatment initiation factors and cognitive outcome in youth with perinatally acquired HIV infectionJ Rutstein Lazarus, R M Rutstein, E D LowenthalHIV Medicine|October 6, 2012
Cognitive function after several years of antiretroviral therapy with stable central nervous system penetration scoreY Kahouadji, J Dumurgier, P Sellier, et al.HIV Medicine|September 22, 2012
Longitudinal analysis of integrase N155H variants in heavily treated patients failing raltegravir-based regimensH L Nguyen, C Charpentier, N Nguyen, et al.HIV Medicine|September 22, 2012
Pancreatic insufficiency in patients with HIV infection: role of didanosine questionedT C S Martin, A Scourfield, N Rockwood, et al.Pageof 229